Back to search results

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Abroad (travel likely)Recruiting

Conditions

Breast Cancer, Familial Male · Radiotherapy; Complications · Chemotherapeutic Toxicity · Immune Checkpoint Inhibitor · CDK4/6 Inhibitor · Trastuzumab · Pertuzumab · PARP Inhibitor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Yirui Zhai, MD) · januarywind@163.com · +86-10-87788058
    Contact: Study coordinator (Bo Lan, MD.) · daxiaolanbo@163.com
Study leads

  • Yirui Zhai, MD

    Principal Investigator

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Bo Lan, MD

    Principal Investigator

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Shulian Wang, MD

    Study Chair

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Fei Ma, MD

    Study Chair

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

View source on ClinicalTrials.gov(opens in a new tab)